Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference

Key Terms

phase 3 medical

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

open-label medical

Open-label describes a situation where everyone involved in a study or process knows the full details, such as who is receiving a treatment or intervention. For investors, understanding whether a project or product is open-label helps gauge the level of transparency and potential biases, influencing trust and decision-making. It’s like knowing whether a test or experiment is conducted openly or behind closed doors.

biomarker medical

A biomarker is a measurable indicator found in the body, such as in blood or tissues, that provides information about health, disease, or how the body responds to treatment. For investors, biomarkers can signal the potential success or risk of medical products or therapies, influencing the value of related companies and industry trends. They act like signals or clues that help assess the progress of medical advancements and their market impact.

real-world evidence medical

Real-world evidence is information gathered from everyday sources like patient records, insurance claims, or everyday experiences, rather than controlled experiments or clinical trials. It helps investors understand how products or policies perform in real life, providing a more complete picture of their effectiveness and value beyond official tests. This type of evidence can influence decision-making by offering insights based on actual, everyday outcomes.

poster presentations technical

Poster presentations are visual summaries of research findings displayed at scientific conferences on large boards or electronic screens, often accompanied by a brief in-person explanation. They matter to investors because they reveal early or detailed data about a drug, device, or study outcome before full publication; think of them as a research preview or trade-show demo that can change expectations about a product’s prospects once results are seen and discussed.

industry theater technical

Industry theater describes public actions, announcements or demonstrations by companies or trade groups designed mainly to create the appearance of progress, leadership or safety without meaningful change behind the scenes. For investors it matters because these gestures can mask weak fundamentals or ongoing risks, leading to overconfidence, mispriced shares or sudden corrections when substance is demanded — like painting a house to look fixed while the foundation is untouched.

mini symposium technical

A mini symposium is a short, focused meeting or session where experts present and discuss a specific scientific or regulatory topic, often featuring brief talks, panels, and Q&A. For investors, it matters because these concentrated presentations can reveal new data, expert opinions or regulatory views that may change how a product or company is valued—think of it as a targeted news briefing that can move market expectations.

poster discussion technical

A poster discussion is a conference session where researchers display study summaries on posters and briefly explain their findings to small groups, answering questions from peers and experts—think of it like a gallery walkthrough where the scientist stands by their work to talk through key points. For investors, poster discussions matter because they reveal early, often detailed data and how experts react to it, helping gauge scientific credibility, potential regulatory paths, and the likelihood that results will support future commercial or clinical progress.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

-- All Presentations Include New Data from the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP), Including Data from the Ongoing Open-Label Treatment Period --

-- Company to Host Industry Theater on aPAP with Renowned Key Opinion Leaders --

LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of one oral presentation and two poster presentations at the ATS International Conference in Orlando, Florida, May 17-20, 2026.

Oral Presentation

Title: Molgramostim Improves Exercise Distance and Duration in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP): Results from the IMPALA-2 Phase 3 Clinical Trial
Mini Symposium: B95 – Fibrosis, Cough, and Inflammation: Treatment Strategies in ILD
Abstract Number: 9296
Date/Time: Monday, May 18, 2026, 2:51 - 3:03 PM EDT
Location: W304 E-H Level III, Orange County Convention Center, West Concourse
Presenter: Cormac McCarthy, M.D., Ph.D., FRCPI, Associate Professor of Medicine, University College Dublin (UCD) and Consultant Respiratory Physician, St. Vincent’s University Hospital, Dublin, Ireland

Poster Presentations

Title: Long-term Efficacy and Safety of Molgramostim in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP): Results from the IMPALA-2 Trial Open-Label Treatment Period
Poster Discussion: C104 - Therapeutics, Biomarkers, and Real-World Evidence in ILD
Poster Board: #403
Abstract Number: 9330
Date/Time: Tuesday, May 19, 2026, 2:15 - 4:15 PM EDT
Location: W230 Level II, Orange County Convention Center, West Concourse
Presenter: Bruce Trapnell, M.D., Professor of Medicine and Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH

Title: Relationship Between Pulmonary Gas Transfer and Biomarker Levels in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Poster Discussion: D23 – Molecular Profiling to Patient-Reported Outcomes – Integrating Phenotypes and Real-World Data in ILD
Poster Board: #401
Abstract Number: 9080
Date/Time: Wednesday, May 20, 2026, 8:15 - 10:15 AM EDT
Location: W230 Level II, Orange County Convention Center, West Concourse
Presenter: Yoshikazu Inoue, M.D., Ph.D., Executive Director of the Clinical Research Center, NHO Kinki Chuo Chest Medical Center and Internal Medicine, Osaka Anti-Tuberculosis Association Osaka Fukujuji Hospital, Osaka, Japan

ATS Industry Theater

Title: Advances in aPAP: From Pathophysiology to Patient Experience
Date/Time: Monday, May 18, 2025, 1:00 - 2:00 PM EDT
Location: Exhibit Hall, Innovation Theater 6
Description: Kevin Davidson, M.D., FCCP, will present an update on aPAP, addressing pathophysiology, clinical presentation, diagnosis, and management, followed by a discussion moderated by Jeff Sippel, M.D., incorporating insights from his clinical experience and the lived experience of Kelsea A., a patient advocate living with aPAP.

About Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Autoimmune PAP is a rare lung disease characterized by the abnormal build-up of surfactant in the alveoli. Surfactant consists of proteins and lipids and is an important physiological substance that lines the alveoli to prevent them from collapsing. In a healthy lung, excess surfactant is cleared and digested by immune cells called alveolar macrophages. Alveolar macrophages need to be stimulated by granulocyte-macrophage colony-stimulating factor (GM-CSF) to function properly in clearing surfactant, but in aPAP, GM-CSF is neutralized by antibodies against GM-CSF, rendering macrophages unable to adequately clear surfactant. As a result, an excess of surfactant accumulates in the alveoli, causing impaired gas exchange, resulting in clinical symptoms of shortness of breath, often with cough and frequent fatigue. Patients may also experience episodes of fever, chest pain, or coughing up blood, especially if secondary lung infection develops. In the long term, the disease can lead to serious complications, including lung fibrosis and the need for a lung transplant.

About Savara

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim inhalation solution (molgramostim) is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via a proprietary investigational eFlow^® Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of molgramostim. Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260414233320/en/

Media and Investor Contact:
Savara Inc.
Temre Johnson, Executive Director, Corporate Affairs
ir@savarapharma.com

Source: Savara Inc.